X4 Pharmaceuticals Appoints Dr. Sudha Parasuraman as Chief Medical Officer

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare diseases, today announced the appointment of Dr. Sudha Parasuraman as Chief Medical Officer. Dr. Parasuraman is a board-certified hematologist and oncologist with a strong clinical background and deep experience in all phases of oncology drug development.

This entry was posted in Recent Development News: Q1 - 2017, Recent Developments. Bookmark the permalink.
Read Full Article »